Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells

References

• Barrett J W, Shun Chang C, Wang G, Werden S J, Shao Z, Barrett C, Gao X, Belsito T A, Villenevue D, McFadden G. Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Virology 2007a; 361: 123–132
   Google Scholar
• Barrett J W, Sypula J, Wang F, Alston L R, Shao Z, Gao X, Irvine T S, McFadden G. M135R is a novel cell surface virulence factor of myxoma virus. J Virol 2007b; 81: 106–114
   Google Scholar
• Barry M, Hnatiuk S, Mossman K, Lee S F, Boshkov L, McFadden G. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes. Virology 1997; 239: 360–377
   PubMedGoogle Scholar
• Franken N A, Rodermond H M, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315–2319
   PubMed Web of Science ®Google Scholar
• Gaddy D F, Lyles D S. Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol 2007; 81: 2792–2804
   PubMed Web of Science ®Google Scholar
• Hill C, Hunter S B, Brat D J. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 2003; 10: 212–217
   PubMedGoogle Scholar
• Hnatiuk S, Barry M, Zeng W, Liu L, Lucas A, Percy D, McFadden G. Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis. Virology 1999; 263: 290–306
   Google Scholar
• Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens A C, Van Meir E G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469–479
   PubMed Web of Science ®Google Scholar
• Johnston J B, McFadden G. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol 2004; 9: 695–705
   Google Scholar
• King G D, Curtin J F, Candolfi M, Kroeger K, Lowenstein P R, Castro M G. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2005; 5: 535–557
   PubMed Web of Science ®Google Scholar
• Knobbe C B, Trampe-Kieslich A, Reifenberger G. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 2005; 31: 486–490
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S I, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner S H, Giovanella B C, Ittmann M, Tycko B, Hibshoosh H, Wigler M H, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943–1947
   PubMed Web of Science ®Google Scholar
• Liu T C, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101–117
   PubMedGoogle Scholar
• Liu T C, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007; 67: 429–432
   PubMed Web of Science ®Google Scholar
• Lun X, Yang W, Alain T, Shi Z-Q, Muzik H, Barrett J W, McFadden G, Bell J, Hamilton M G, Senger D L, Forsyth P A. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005; 65: 9982–9990
   PubMed Web of Science ®Google Scholar
• Macen J L, Graham K A, Lee S F, Schreiber M, Boshkov L K, McFadden G. Expression of the myxoma virus tumor necrosis factor receptor homologue (T2) and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology 1996; 218: 232–237
   Google Scholar
• Macen J L, Upton C, Nation N, McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 1993; 195: 348–363
   Google Scholar
• McFadden G. Poxvirus Tropism. Nature Reviews Microbiology 2005; 3: 201–213
   PubMed Web of Science ®Google Scholar
• Mellinghoff I K, Wang M Y, Vivanco I, Haas-Kogan D A, Zhu S, Dia E Q, Lu K V, Yoshimoto K, Huang J H, Chute D J, Riggs B L, Horvath S, Liau L M, Cavenee W K, Rao P N, Beroukhim R, Peck T C, Lee J C, Sellers W R, Stokoe D, Prados M, Cloughesy T F, Sawyers C L, Mischel P S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012–2024
   PubMed Web of Science ®Google Scholar
• Merrill M K, Selznick L A, Gromeier M. Oncolytic viruses fro the treatment of malignant glioma. Expert Opin Ther Patents 2006; 16: 363–371
   Web of Science ®Google Scholar
• Mossman K, Lee S F, Barry M, Boshkov L, McFadden G. Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J Virol 1996; 70: 4394–4410
   PubMed Web of Science ®Google Scholar
• Nash P, Barry M, Seet B T, Veugelers K, Hota S, Heger J, Hodgkinson C, Graham K, Jackson R J, McFadden G. Post-translational modification of the myxoma-virus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase. Biochem J 2000; 347: 375–382
   Google Scholar
• Opgenorth A, Graham K, Nation N, Strayer D, McFadden G. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J Virol 1992; 66: 4720–4731
   PubMed Web of Science ®Google Scholar
• Parato K A, Senger D, Forsyth P A, Bell J C. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965–976
   PubMed Web of Science ®Google Scholar
• Rao R D, James C D. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin Oncol 2004; 31: 595–604
   PubMed Web of Science ®Google Scholar
• Roberts M S, Lorence R M, Groene W S, Bamat M K. Naturally oncolytic viruses. Curr Opin Mol Ther 2006; 8: 314–321
   PubMed Web of Science ®Google Scholar
• Schreiber M, Sedger L, McFadden G. Distinct domains of M-T2, the myxoma virus TNF receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol 1997; 71: 2171–2181
   Google Scholar
• Stanford M M, Barrett J W, Nazarian S H, Werden S, McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 2007; 81: 1251–1260
   PubMed Web of Science ®Google Scholar
• Steck P A, Pershouse M A, Jasser S A, Yung W K, Lin H, Ligon A H, Langford L A, Baumgard M L, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng D H, Tavtigian S V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356–362
   PubMed Web of Science ®Google Scholar
• Stojdl D F, Lichty B D, ten Oever B R, Paterson J M, Power A T, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown E G, Durbin R K, Durbin J E, Hiscott J, Bell J C. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263–275
   PubMed Web of Science ®Google Scholar
• Sypula J, Wang F, Ma Y, Bell J, McFadden G. Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 2004; 8: 103–114
   Google Scholar
• Tong A. Oncolytic viral therapy for human cancer: challenges revisited. Drug Dev Res 2006; 66: 260–277
   Web of Science ®Google Scholar
• Upton C, Macen J L, Schreiber M, McFadden G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 1991; 184: 370–382
   PubMed Web of Science ®Google Scholar
• Upton C, Mossman K, McFadden G. Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Science 1992; 258: 1369–1372
   PubMed Web of Science ®Google Scholar
• Wang G, Barrett J W, Stanford M, Werden S J, Johnston J B, Gao X, Sun M, Cheng J Q, McFadden G. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 2006; 103: 4640–4645
   PubMed Web of Science ®Google Scholar
• Werden S J, Barrett J W, Wang G, Stanford M M, McFadden G. M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol 2007; 81: 2340–2348
   Google Scholar
• Wollmann G, Robek M D, van den Pol A N. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol 2007; 81: 1479–1491
   Web of Science ®Google Scholar
• Wollmann G, Tattersall P, van den Pol A N. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol 2005; 79: 6005–6022
   PubMed Web of Science ®Google Scholar
• Woo Y, Adusumilli P S, Fong Y. Advances in oncolytic viral therapy. Curr Opin Investig Drugs 2006; 7: 549–559
   PubMed Web of Science ®Google Scholar